News
Learn from NIH’s Michael Salgaller on how to partner with NIH at the Seoul Bio Forum on June 22, 2026. This forum is intended to bring together South Korean biotech and pharma companies with U.S. investors, research institutions, and industry leaders. He will be discussing NIH as a premier
NIH inventors have developed a mutation-independent method to treat Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), other inherited retinal degenerations (IRDs), and age-related macular degeneration (AMD) using the FDA-approved small molecule, Halofantrine. NIH inventors found
Company Overview: AUTM is the nonprofit leader in efforts to educate, promote and inspire professionals – throughout their careers – to support the development of academic research that changes the world. AUTM’s community is comprised of more than 3,000 members who work in more than 800 universities
Age-related macular degeneration (AMD) affects approximately 200 million people worldwide and is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late-stage AMD would allow timely medical treatments, lifestyle interventions, more tailored